Health Care Costs Set To Rise: NCHC

20 April 1997

US health care costs will rise 2-2.5 times as fast as inflation over thenext five years, according to a new study commissioned by the National Coalition on Health Care. Middle class families will pay a greater percentage of their income on health care than any other group, it was noted, while married couples with children will pay 5.5% above inflation and single-parent families as much as 10% more than inflation for their health care costs.

The slower growth in health care spending of the last two years has subsided, according to the study, conducted for the NCHC by the Tulane University Medical Center Institute for Health Service Research, and costs are now expected to rise by 6.4% annually, beginning this year, and there will be continued acceleration over the next five years.

The study projects that in 1997, the typical family will directly spend $2,000 on health care, including health care insurance, pharmaceuticals and medical supplies. Almost 50% of the out-of-pocket expenses are directly attributable to insurance premiums, with the costs of paying for the uninsured being shifted at a greater percentage cost onto the middle class than the affluent. Based on the study, health care now accounts for about 13.8% of the USA's Gross Domestic Product, and will rise to almost 15% by 2002.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight